title: A transgenic mouse model for tumour immunotherapy: induction of an anti-idiotype response to human MUC1.
abstract: MUC1 is a membrane bound, polymorphic epithelial mucin expressed at the luminal surface of glandular epithelium. It is highly expressed in an underglycosylated form on carcinomas and metastatic lesions and is, therefore, a potential target for immunotherapy of cancer. The monoclonal antibody HMFG1 binds the linear core protein sequence, PDTR, contained within the immunodominant domain of the tandem repeat of MUC1. The efficacy of murine and humanized HMFG1 (Ab1) used as an anti-idiotypic vaccine was examined in mice transgenic for human MUC1 (MUC1.Tg) challenged with murine epithelial tumour cells transfected with human MUC1. Humoral idiotypic cascade through Ab2 and Ab3 antibodies was observed in MUC1.Tg mice following multiple antibody inoculations in the presence of adjuvant. Impaired tumour growth at day 35 and highest Ab3 levels were found in mice that had received mHMFG1 with RAS adjuvant. However, comparison of Ab3 levels in individual mice with tumour size in all treatment groups did not show a correlation between smaller tumours and increased levels of anti-idiotype antibody. This suggests that the anti-tumour effects of anti-idiotype vaccination are not solely related to the induction of idiotypic antibody cascades and probably involve other mechanisms.
authors.affiliation: Applied Developmental Laboratory, Imperial Cancer Research Technology,St. Bartholomew's Hospital, London, UK.
authors.forename: R W
authors.initials: RW
authors.lastname: Wilkinson
authors.forename: E L
authors.initials: EL
authors.lastname: Ross
authors.forename: A E
authors.initials: AE
authors.lastname: Lee-MacAry
authors.forename: R
authors.initials: R
authors.lastname: Laylor
authors.forename: J
authors.initials: J
authors.lastname: Burchell
authors.forename: J
authors.initials: J
authors.lastname: Taylor-Papadimitriou
authors.forename: D
authors.initials: D
authors.lastname: Snary
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008808:Mice, Inbred CBA; D008822:Mice, Transgenic; D018396:Mucin-1 / Q000276:immunology; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D014407:Tumor Cells, Cultured
chemical_list: D000276:Adjuvants, Immunologic; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D018396:Mucin-1